Healthcare Industry News: Ipsen
News Release - May 17, 2011
Former Pharma Executive, Dr. Dominique Bridon, Joins Optivia Senior ManagementMENLO PARK, Calif.--(Healthcare Sales & Marketing Network)-- Optivia Biotechnology Inc., a pioneer in the field of transporter biology and leading provider of in vitro transporter assay services, today announced the appointment of Dominique Bridon, Ph.D., as executive vice president and chief operating officer.
Dr. Bridon brings more than 20 years of strategic planning, financing and research management experience to Optivia. Most recently, he served as senior vice president of research and innovation at the Ipsen Group, an international specialty pharmaceutical group. In this position, Dr. Bridon was responsible for the drug discovery, translational research and formulation teams in the U.S. and Europe, and also managed all external research partnerships and collaborations. Prior to Ipsen, from 1997 to 2006, Dr. Bridon served as vice president of research and chief technical officer of ConjuChem, a company he co-founded in Montreal, Canada. He previously served as director of biological chemistry for Redcell, Inc. in South San Francisco. From 1989 through 1996, Dr. Bridon held various scientific positions at Abbott Laboratories in the diagnostic and pharmaceutical research areas.
“Dominique’s extensive experience as an innovator, manager and strategic planner in the pharmaceutical and diagnostic industries will be invaluable as Optivia seeks to extend its global leadership in transporter biology,” said Yong Huang, Ph.D., Optivia president and chief executive officer. “In his new position, he will help to guide Optivia’s international expansion as well as its entry into new fields.”
“This is an exciting time to be joining Optivia as it works to broaden applications of its industry-leading transporter biology platform,” stated Dr. Bridon. “We aim not only to provide cutting-edge tools and assays for assessing dangerous drug-drug interactions (DDIs), but to help optimize drug efficacy through improved drug absorption and tissue distribution, discover new avenues for drug target discovery, and develop improved methods for diagnostic imaging.”
Transporters are a class of 300 to 400 proteins that act as nature’s “gatekeepers,” facilitating the movement of drugs and other substances into and out of cells. As such, transporters play a vital role in drug response and safety, physiology and disease biology.
About Optivia Biotechnology
Based in Menlo Park, CA, Optivia Biotechnology, Inc. is a leader in transporter biology research and transporter assay services. Optivia develops and provides a comprehensive set of transporter assays, databases and models to help in the discovery and development of drugs with improved safety and efficacy. For more information, please visit www.optiviabio.com.
Source: Optivia Biotechnology
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.